ホーム › 悪性黒色腫 › ワシントン

ワシントンにおける悪性黒色腫の臨床試験

ワシントン内の拠点で、悪性黒色腫に関する25件の研究が参加者を募集しています。

ワシントン内の都市

公式研究テキスト（英語）

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
他19件

被験者募集中観察研究健康なボランティア歓迎

40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

Fred Hutchinson Cancer Center ( Site 4041), Seattle

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT06961006

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Swedish Cancer Institute - Edmonds Campus, Edmonds
Swedish Cancer Institute - Issaquah Campus, Issaquah
Kadlec Clinic Hematology and Oncology, Kennewick
他1件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06246916

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Swedish Cancer Institute, Edmonds

被験者募集中第3相

18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT05727904

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Northwest Medical Specialties, Tacoma

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/24更新 · NCT06047379

Pan-tumor MRD Study

Northwest Medical Specialties (NWMS), Tacoma

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

Fred Hutchinson Cancer Center, Seattle
University of Washington Medical Center - Montlake, Seattle
Saint Joseph Medical Center Hematology and Oncology - Silverdale, Silverdale

被験者募集中第3相

75歳以上 · 全性別 · 2026/09/24更新 · NCT07068074

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

University of Washington Fred Hutchinson Cancer Center, Seattle

被験者募集中第1/2相

18歳〜99歳 · 全性別 · 2026/09/22更新 · NCT06814496

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Local Institution - 0086, Seattle

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/16更新 · NCT07492680

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Providence Regional Cancer System-Aberdeen, Aberdeen
PeaceHealth Saint Joseph Medical Center, Bellingham
Providence Regional Cancer System-Centralia, Centralia
他15件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/15更新 · NCT04511013

Project: Every Child for Younger Patients With Cancer

Seattle Children's Hospital, Seattle
Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Mary Bridge Children's Hospital and Health Center, Tacoma
他1件

被験者募集中観察研究

25歳以下 · 全性別 · 2026/08/25更新 · NCT02402244

High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial

Fred Hutch/University of Washington Cancer Consortium, Seattle

被験者募集中

18歳以上 · 全性別 · 2026/08/19更新 · NCT06298734

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

Wenatchee Valley Hospital and Clinics, Wenatchee

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/05更新 · NCT06330064

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Summit Cancer Center, Spokane

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

Fred Hutch/University of Washington Cancer Consortium, Seattle

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/22更新 · NCT05098210

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

USA09-0, Puyallup
USA07-0, Spokane

被験者募集中第2相

18歳以上 · 全性別 · 2026/05/22更新 · NCT06953089

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Virginia Mason Medical Center, Seattle

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/05/15更新 · NCT05379985

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

Fred Hutchinson Cancer Center, Seattle

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/05/13更新 · NCT03686124

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Fred Hutchinson Cancer Center, Seattle

被験者募集中第2/3相

全年齢 · 全性別 · 2026/04/02更新 · NCT06581406

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Kaiser Permanente Bellevue Medical Center, Bellevue
Swedish Cancer Institute-Edmonds, Edmonds
Swedish Cancer Institute-Issaquah, Issaquah
他5件

被験者募集中観察研究

18歳以上 · 全性別 · 2026/03/17更新 · NCT06418204

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Fred Hutchinson Cancer Center, Seattle

被験者募集中第3相

18歳以上 · 全性別 · 2026/02/25更新 · NCT05549297

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Research Site 105, Spokane

被験者募集中第1/2相

18歳以上 · 全性別 · 2025/11/21更新 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Seattle

被験者募集中観察研究

全年齢 · 全性別 · 2025/10/28更新 · NCT03452774

BostonGene and Exigent Genomic INsight Study

Northwest Medical Specialities, Puyallup

被験者募集中観察研究

18歳以上 · 全性別 · 2025/02/17更新 · NCT06272864

A Study of IBI363 in Subjects with Advanced Solid Malignancies

Fred Hutchinson Cancer Center, Seattle

被験者募集中第2相

18歳以上 · 全性別 · 2024/12/19更新 · NCT06281678

ClinicalTrials.govより、2026/10/04時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。